Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mila Etropolski

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Advances in Therapy|April 16, 2011
Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxycodone hydrochlorideMila Etropolski, Kathleen Kelly, Akiko Okamoto, et al.
The AAPS Journal|December 23, 2011
On average: data exploration based on means can be misleadingAdrian Dunne, Mila Etropolski, An Vermeulen, et al.
The American Journal of Gastroenterology|November 11, 2010
Validation of a bowel function diary for assessing opioid-induced constipationMichael Camilleri, Margaret Rothman, Kai Fai Ho, et al.
Journal of Opioid Management|November 5, 2015
Tolerability and efficacy of tapentadol extended release in elderly patients ≥ 75 years of age with chronic osteoarthritis knee or low back painDavid M Biondi, Jim Xiang, Mila Etropolski, et al.
Clinical Drug Investigation|June 12, 2014
Evaluation of blood pressure and heart rate in patients with hypertension who received tapentadol extended release for chronic pain: a post hoc, pooled data analysisDavid M Biondi, Jim Xiang, Mila Etropolski, et al.
BMC Psychiatry|January 5, 2020
Treatment patterns and sequences of pharmacotherapy for patients diagnosed with depression in the United States: 2014 through 2019David M Kern, M Soledad Cepeda, Frank Defalco, et al.
Journal of Opioid Management|December 20, 2013
A pooled analysis of patient-specific factors and efficacy and tolerability of tapentadol extended release treatment for moderate to severe chronic painMila Etropolski, Bernd Lange, Jutta Goldberg, et al.
Journal of Opioid Management|May 28, 2013
Composite measure to assess efficacy/gastrointestinal tolerability of tapentadol ER versus oxycodone CR for chronic pain: pooled analysis of randomized studiesSanjay Merchant, David Provenzano, Samir Mody, et al.
Pain Physician|May 25, 2013
Tapentadol immediate release versus oxycodone immediate release for treatment of acute low back painDavid Biondi, Jim Xiang, Carmela Benson, et al.
Clinical Drug Investigation|November 18, 2016
Quantifying the Exposure of Tapentadol Extended Release in Japanese Patients with Cancer Pain and Bridging Tapentadol Pharmacokinetics Across Populations Using a Modeling ApproachLiping Zhang, Xiaoyu Yan, Sayori Nobe, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Advances in Therapy|April 16, 2011
Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxycodone hydrochlorideMila Etropolski, Kathleen Kelly, Akiko Okamoto, et al.
The AAPS Journal|December 23, 2011
On average: data exploration based on means can be misleadingAdrian Dunne, Mila Etropolski, An Vermeulen, et al.
The American Journal of Gastroenterology|November 11, 2010
Validation of a bowel function diary for assessing opioid-induced constipationMichael Camilleri, Margaret Rothman, Kai Fai Ho, et al.
Journal of Opioid Management|November 5, 2015
Tolerability and efficacy of tapentadol extended release in elderly patients ≥ 75 years of age with chronic osteoarthritis knee or low back painDavid M Biondi, Jim Xiang, Mila Etropolski, et al.
Clinical Drug Investigation|June 12, 2014
Evaluation of blood pressure and heart rate in patients with hypertension who received tapentadol extended release for chronic pain: a post hoc, pooled data analysisDavid M Biondi, Jim Xiang, Mila Etropolski, et al.
BMC Psychiatry|January 5, 2020
Treatment patterns and sequences of pharmacotherapy for patients diagnosed with depression in the United States: 2014 through 2019David M Kern, M Soledad Cepeda, Frank Defalco, et al.
Journal of Opioid Management|December 20, 2013
A pooled analysis of patient-specific factors and efficacy and tolerability of tapentadol extended release treatment for moderate to severe chronic painMila Etropolski, Bernd Lange, Jutta Goldberg, et al.
Journal of Opioid Management|May 28, 2013
Composite measure to assess efficacy/gastrointestinal tolerability of tapentadol ER versus oxycodone CR for chronic pain: pooled analysis of randomized studiesSanjay Merchant, David Provenzano, Samir Mody, et al.
Pain Physician|May 25, 2013
Tapentadol immediate release versus oxycodone immediate release for treatment of acute low back painDavid Biondi, Jim Xiang, Carmela Benson, et al.
Clinical Drug Investigation|November 18, 2016
Quantifying the Exposure of Tapentadol Extended Release in Japanese Patients with Cancer Pain and Bridging Tapentadol Pharmacokinetics Across Populations Using a Modeling ApproachLiping Zhang, Xiaoyu Yan, Sayori Nobe, et al.
Pageof 3